Pharmaceutical Contract Sales Outsourcing Market (By Service: Personal Promotion, Non-personal Promotion, Others; By Therapeutic Area: Oncology, Cardiovascular Disorders, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Pharmaceutical Contract Sales Outsourcing Market, By Service

7.1.  Pharmaceutical Contract Sales Outsourcing Market, by Service, 2021-2030

7.1.1.     Personal Promotion

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     Non-personal Promotion

7.1.2.1.          Market Revenue and Forecast (2016-2030)

7.1.3.     Others (Field Management/Reporting and Sales Training)

7.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Pharmaceutical Contract Sales Outsourcing Market, By Therapeutic Area

8.1.  Pharmaceutical Contract Sales Outsourcing Market, by Therapeutic Area, 2021-2030

8.1.1.     Cardiovascular Disorders

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Oncology

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Metabolic Disorders

8.1.3.1.          Market Revenue and Forecast (2016-2030)

8.1.4.     Neurology

8.1.5.     Market Revenue and Forecast (2016-2030)

8.1.6.     Orthopedic Diseases

8.1.6.1.          Market Revenue and Forecast (2016-2030)

8.1.7.     Infectious Diseases

8.1.7.1.          Market Revenue and Forecast (2016-2030)

8.1.8.     Others

8.1.8.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Pharmaceutical Contract Sales Outsourcing Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.     Market Revenue and Forecast, by Service (2016-2030)

9.1.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.1.3.     U.S.

9.1.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.1.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.1.4.     Rest of North America

9.1.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.1.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.  Europe

9.2.1.     Market Revenue and Forecast, by Service (2016-2030)

9.2.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.3.     UK

9.2.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.4.     Germany

9.2.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.5.     France

9.2.5.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.5.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.6.     Rest of Europe

9.2.6.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.6.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.  APAC

9.3.1.     Market Revenue and Forecast, by Service (2016-2030)

9.3.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.3.     India

9.3.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.4.     China

9.3.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.5.     Japan

9.3.5.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.5.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.6.     Rest of APAC

9.3.6.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.6.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.  MEA

9.4.1.     Market Revenue and Forecast, by Service (2016-2030)

9.4.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.3.     GCC

9.4.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.4.     North Africa

9.4.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.5.     South Africa

9.4.5.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.5.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.6.     Rest of MEA

9.4.6.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.6.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.5.  Latin America

9.5.1.     Market Revenue and Forecast, by Service (2016-2030)

9.5.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.5.3.     Brazil

9.5.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.5.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.5.4.     Rest of LATAM

9.5.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.5.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

Chapter 10.   Company Profiles

10.1.                 Ashfield (UDG Healthcare plc)

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.                 inVentiv Health

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.                 Inc. (Syneos Health)

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.                 IQVIA

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.                 Granard Pharmaceutical Sales & Marketing

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.                 Vanguard Pharma Inc.

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.                 GTS Solution

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.                 EVERSANA

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.                 MaBiCo

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.              MaBiCo

10.10.1.                   Company Overview

10.10.2.                   Product Offerings

10.10.3.                   Financial Performance

10.10.4.                   Recent Initiatives

Chapter 11.   Research Methodology

11.1.                 Primary Research

11.2.                 Secondary Research

11.3.                 Assumptions

Chapter 12.   Appendix

12.1.                 About Us

12.2.                 Glossary of Terms

Report Details

  • Report Code:38524
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:September 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers